2015
DOI: 10.3111/13696998.2015.1067622 View full text |Buy / Rent full text
|
|

Abstract: Compared with insulin glargine QD, exenatide BID as add-on therapy to OAD is a cost-effective treatment in Chinese patients inadequately controlled by OAD treatments.

Help me understand this report

Search citation statements

Order By: Relevance
Select...
0
9
0

Publication Types

Select...

Relationship

0
0

Authors

Journals